SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is actively trending following its announced all-stock merger with fusion power company TAE Technologies. This unexpected strategic pivot into the highly speculative fusion energy sector, aimed at future AI power demand, has sparked intense debate among market participants. Enthusiastic supporters hail it as a transformative "moonshot" with significant upside, while detractors characterize it as a high-risk speculative play, citing the company's evolving business focus and the long-term viability challenges of commercial fusion energy.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab (RKLB) is trending following its substantial $805 million contract award from the Space Development Agency, solidifying its position among major defense primes. The community is buzzing with excitement over this significant validation and the company's accelerated U.S. Space Force mission, viewing RKLB as a pivotal long-term player in the rapidly expanding space sector with high anticipation for its upcoming Neutron rocket developments.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending with significant bullish momentum, largely fueled by a recent KeyBanc "Overweight" rating and a $20 price target, alongside widespread anticipation for the imminent NASA Lunar Terrain Vehicle (LTV) contract award. The community is actively discussing the stock's high short interest, speculating on a potential squeeze, and highlighting the broader sector enthusiasm for lunar exploration and infrastructure as key drivers for substantial upside.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending lower after its earnings report, despite beating EPS and revenue estimates, due to concerns over plunging sales in China and declining gross margins from tariffs. The community is sharply divided, with many questioning the stock's high valuation and future growth prospects amidst increasing competition and discussions around its brand image. While some view the dip as a long-term buying opportunity, others predict further downside.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending due to widespread anticipation of a short squeeze, fueled by its extremely low float and high cost-to-borrow. The community is actively discussing bullish technical setups and significant breakout potential, drawing comparisons to recent parabolic movers in the low-float market. Furthermore, its operations in IoT and security solutions, including substantial contracts, contribute to the optimistic outlook.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival is trending due to its significant financial turnaround, highlighted by the reinstatement of its quarterly dividend and robust earnings performance. The community is actively celebrating this return to profitability, with many expressing confidence in sustained growth and a positive outlook for the cruise operator's long-term value.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is a hot topic, with considerable community speculation around a potential short squeeze given its low float and persistent underperformance compared to peers like Rivian. Despite its premium electric vehicles consistently earning industry accolades and excitement around partnerships for autonomous technology and future mid-size models, many investors voice frustration with management's execution and the stock's valuation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as excitement builds around its expanded hands-free driving features and robust AI strategy, including custom chips and the anticipated R2 platform. The community is actively discussing recent analyst re-ratings that highlight its long-term potential, fueling a strong "short squeeze" narrative as the stock approaches new highs. This momentum reflects a growing conviction in Rivian's technological advancements and future competitive position in the EV market.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending following significant contract announcements, including an eight-figure deal for European spacecraft docking systems and a $44 million DARPA contract, underscoring its pivotal role in the expanding space and defense sectors. The community is actively discussing RDW's diverse portfolio in space infrastructure, in-space manufacturing, and drone technology, with many believing the stock is currently undervalued despite recent volatility. There is a strong long-term bullish sentiment driven by anticipated growth in commercial and defense space initiatives.

Starfighters Space Inc

Starfighters Space Inc (FJET) is captivating traders as a recent market entrant in the aerospace sector, uniquely positioned with commercial supersonic flight and payload launch capabilities from NASA's Kennedy Space Center. The stock's debut has ignited significant community speculation and volatility, with many expressing highly bullish sentiment and anticipating substantial growth, often drawing parallels to broader interest in the space industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Amicus...

<ul class="summary-bullets"><li>The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday.</li><li>Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold.</li><li>BioMarin plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt</li></ul>Amicus Therapeutics (FOLD) shares jumped more than 30% in on Friday, to their highest level since January 2024, after BioMarin Pharmaceutical (BMRN) agreed to acquire the company in a $4.8 billion all-cash deal.The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. The transaction is expected to close in the second quarter of fiscal 2026. Biomarin shares gained 6.6%.Both <a href="https://stocktwits.com/symbol/FOLD">FOLD</a> and <a href="https://stocktwits.com/symbol/BMRN">BMRN</a> were among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Portfolio Expansion And Revenue Pipeline</h2>The acquisition will expand BioMarin’s portfolio, adding two new treatments to its existing medicines for rare inherited metabolic disorders.Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease generated $599 million in combined net revenues over the past four quarters. U.S. exclusivity for Galafold is projected through January 2037 following recent patent settlements.The deal is expected to boost revenue as soon as it closes and add to earnings within the first year. BioMarin expects the acquisition to become meaningfully more accretive from 2027.The company plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt, with Morgan Stanley providing a bridge financing commitment.<h2 class="st-heading-2">IP Dispute Update</h2>Separately, Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold. Under the agreements, the companies will be allowed to launch generics in the U.S. starting January 30, 2037, subject to FDA approval.As part of the settlement, all ongoing Hatch-Waxman litigation between the parties will be terminated, and U.S. antitrust authorities will review the agreements.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for Biomarin on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high' message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:904/100;" src="https://news.stocktwits-cdn.com/BMRN_png_a8236939f5.webp" alt="BMRN.png" width="904" height="100"><figcaption>BMRN's Sentiment Meter And Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>One user highlighted the visibility of BMRN’s FY2027 revenue target.<stembedurl>https://stocktwits.com/DairyQueen505/message/639674012</stembedurl>Retail sentiment for Amicus on the platform remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high message volumes.<figure class="image"><img style="aspect-ratio:922/99;" src="https://news.stocktwits-cdn.com/fold_png_a408903f4b.webp" alt="fold.png" width="922" height="99"><figcaption>FOLD's Sentiment Meter and Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>Year-to-date, FOLD stock has gained 15% while BMRN has declined over 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-new-product-launch-is-lifting-amesite-shares-premarket/cLeiw0iREs7">This New Product Launch Is Lifting Amesite Shares Premarket — Here’s What Investors Are Watching</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal

The acquisition will add two new treatments to BioMarin’s existing medicines for rare inherited metabolic disorders.

Equity

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus...

BioMarin To Acquire Amicus Therapeutics For Around $4.8 Bln

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), a pharmaceutical company, Friday announced that it has entered into a definitive agreement to acquire Amicus Therapeutics (FOLD), a biotech company...

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook BioMarin to Acquire Amicus...

Zacks Industry Outlook Arcutis, Amicus and ANI 

 Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.


5 Biotech Stocks to Watch for Potential Upside

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector. 

Citigroup Initiates Coverage on Amicus Therapeutics (NASDAQ:FOLD)

Citigroup assumed coverage on Amicus Therapeutics in a research note on Wednesday. They set a "buy" rating and a $17.00 price target for the company...

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?

Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.

GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal 

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics Inc

BioMarin is acquiring Amicus Therapeutics for $4.8 billion in an all-cash deal at $14.50 per share, representing a significant premium.

Following the acquisition news, shares experienced a premarket surge of approximately +30%, making it a top gainer.

Traders are speculating which other rare disease or biotech companies could be the next acquisition targets after Amicus Therapeutics' buyout.

FOLD
Amicus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FOLD News

FOLDAmicus Therapeutics Inc